The FDA approval of lenacapavir as a form of preexposure prophylaxis (PrEP) is a major step for HIV prevention, but its ...

Kenya is set to roll out the long-acting injectable HIV Pre-Exposure prophylaxis (PrEP) Lenacapavir by January 2026 following its approval by the World Health Organization.

The World Health Organization (WHO) has recommended the global use of injectable lenacapavir (LEN) twice a year to provide near-total ...

WHO releases new guidelines recommending injectable lenacapavir for HIV prevention: Geneva Wednesday, July 16, 2025, 10:00 Hrs [IST] The World Health Organization (WHO) released n ...

Lenacapavir-a long-acting, six-monthly injectable antiretroviral medicine manufactured by Gilead Sciences-is now recommended by the World Health ...

GENEVA, 15 July 2025–Lenacapavir–a long-acting, six-monthly injectable antiretroviral medicine manufactured by Gilead Sciences–is now recommended by the World Health Organization as an additional HIV ...

A newly approved HIV prevention drug, lenacapavir, is set to be introduced in at least nine countries in early 2026, and ...

WHO director general Tedros Adhanom Ghebreyesus says this new drug—which only needs to be injected twice a year—is the next ...

The World Health Organization (WHO) has included Gilead Sciences' twice-yearly formulation of lenacapavir for pre-exposure ...

A landmark breakthrough in HIV prevention — a scientific feat decades in the making — received final approval from the Food ...

Discover how the WHO's new guidelines on lenacapavir could revolutionise HIV prevention, offering a long-acting alternative to daily pills and addressing the needs of key populations.

South Africa has accepted an offer of just over $29 million (about R520 million) from the Global Fund to Fight Aids, TB and ...